Published in Arthritis Res Ther on July 29, 2011
Treatment for Patients With Osteoarthritis (OA) | NCT00110942
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov (2012) 4.40
Osteoarthritis: a disease of the joint as an organ. Arthritis Rheum (2012) 4.28
The role of synovitis in osteoarthritis pathogenesis. Bone (2012) 2.37
Treating inflammation by blocking interleukin-1 in humans. Semin Immunol (2013) 1.75
Prognostic biomarkers in osteoarthritis. Curr Opin Rheumatol (2013) 1.18
Biologic agents in osteoarthritis: hopes and disappointments. Nat Rev Rheumatol (2013) 1.07
Targeting pro-inflammatory cytokines following joint injury: acute intra-articular inhibition of interleukin-1 following knee injury prevents post-traumatic arthritis. Arthritis Res Ther (2014) 1.04
Interleukin-1 function and role in rheumatic disease. Nat Rev Rheumatol (2015) 1.02
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) (2015) 1.01
New findings in osteoarthritis pathogenesis: therapeutic implications. Ther Adv Chronic Dis (2013) 1.00
Targets, models and challenges in osteoarthritis research. Dis Model Mech (2015) 0.99
Characterization of neopeptides in equine articular cartilage degradation. J Orthop Res (2015) 0.92
Desperately looking for the right target in osteoarthritis: the anti-IL-1 strategy. Arthritis Res Ther (2011) 0.92
Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Res (2016) 0.92
Prospects for treating osteoarthritis: enzyme-protein interactions regulating matrix metalloproteinase activity. Ther Adv Chronic Dis (2012) 0.88
AMPA/kainate glutamate receptors contribute to inflammation, degeneration and pain related behaviour in inflammatory stages of arthritis. Ann Rheum Dis (2013) 0.85
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol (2016) 0.84
Cytokine signaling-1 suppressor is inducible by IL-1beta and inhibits the catabolic effects of IL-1beta in chondrocytes: its implication in the paradoxical joint-protective role of IL-1beta. Arthritis Res Ther (2013) 0.82
An expanding role for interleukin-1 blockade from gout to cancer. Mol Med (2014) 0.82
Human genome-wide expression analysis reorients the study of inflammatory mediators and biomechanics in osteoarthritis. Osteoarthritis Cartilage (2015) 0.81
OsteoRheumatology: a new discipline? RMD Open (2015) 0.75
Cartilage-targeting drug delivery: can electrostatic interactions help? Nat Rev Rheumatol (2017) 0.75
Pigment Epithelium-Derived Factor (PEDF) mediates cartilage matrix loss in an age-dependent manner under inflammatory conditions. BMC Musculoskelet Disord (2017) 0.75
Intra-articular interleukin-1 receptor antagonist (IL1-ra) microspheres for posttraumatic osteoarthritis: in vitro biological activity and in vivo disease modifying effect. J Exp Orthop (2016) 0.75
Generation and functional characterization of anti-human and anti-mouse IL-36R antagonist monoclonal antibodies. MAbs (2017) 0.75
A randomised, placebo-controlled trial of anti-interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease. Respir Res (2017) 0.75
Revisiting the Role of Interleukin-1 Pathway in Osteoarthritis: Interleukin-1α and -1β, and NLRP3 Inflammasome Are Not Involved in the Pathological Features of the Murine Menisectomy Model of Osteoarthritis. Front Pharmacol (2017) 0.75
Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum (1986) 29.12
The role of cytokines in osteoarthritis pathophysiology. Biorheology (2002) 4.28
Nondestructive imaging of human cartilage glycosaminoglycan concentration by MRI. Magn Reson Med (1999) 2.88
Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum (2009) 2.03
Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. Arthritis Rheum (1996) 1.89
In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum (1997) 1.87
Potent inhibition of the master chondrogenic factor Sox9 gene by interleukin-1 and tumor necrosis factor-alpha. J Biol Chem (2000) 1.86
Osteoarthritis: a tale of three tissues. Bull NYU Hosp Jt Dis (2008) 1.84
Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum (2001) 1.66
Role of interleukin-1beta during pain and inflammation. Brain Res Rev (2008) 1.62
Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol (2005) 1.55
Treatment of experimental equine osteoarthritis by in vivo delivery of the equine interleukin-1 receptor antagonist gene. Gene Ther (2002) 1.53
In vivo transfer of interleukin-1 receptor antagonist gene in osteoarthritic rabbit knee joints: prevention of osteoarthritis progression. Am J Pathol (1999) 1.52
Cytokines and inflammation in cartilage degradation. Rheum Dis Clin North Am (1993) 1.33
Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial. Osteoarthritis Cartilage (2007) 1.28
A high interleukin 1 receptor antagonist/IL-1beta ratio occurs naturally in knee osteoarthritis. J Rheumatol (2008) 0.92
Inhibition of adenosine kinase attenuates interleukin-1- and lipopolysaccharide-induced alterations in articular cartilage metabolism. Osteoarthritis Cartilage (2005) 0.87
Cartilage protection by nitric oxide synthase inhibitors after intraarticular injection of interleukin-1beta in rats. Arthritis Rheum (1999) 0.85
Regulation of nitric oxide production in osteoarthritic and rheumatoid cartilage. Role of endogenous IL-1 inhibitors. Scand J Rheumatol (2003) 0.84
Denosumab in postmenopausal women with low bone mineral density. N Engl J Med (2006) 10.02
Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med (2008) 4.39
Assessment of blinding in clinical trials. Control Clin Trials (2004) 3.62
Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum (2008) 3.36
Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain (2008) 2.91
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol (2009) 2.77
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 2.77
Articular cartilage in the knee: current MR imaging techniques and applications in clinical practice and research. Radiographics (2011) 2.70
Quantitative MRI of cartilage and bone: degenerative changes in osteoarthritis. NMR Biomed (2006) 2.64
Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol (2011) 2.62
Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum (2004) 2.62
T2 and T1rho MRI in articular cartilage systems. Magn Reson Med (2004) 2.62
Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction. J Clin Invest (2004) 2.48
Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol (2011) 2.20
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med (2015) 2.17
Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. Arthritis Rheum (2003) 2.14
Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum (2011) 2.11
A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol (2005) 1.95
Assessment of early osteoarthritis in hip dysplasia with delayed gadolinium-enhanced magnetic resonance imaging of cartilage. J Bone Joint Surg Am (2003) 1.93
PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest (2011) 1.88
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol (2009) 1.84
Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. J Rheumatol (2009) 1.77
Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol (2006) 1.60
CD1-mediated gamma/delta T cell maturation of dendritic cells. J Exp Med (2002) 1.56
Short-term morbidity of primary retroperitoneal lymph node dissection in a contemporary group of patients. J Urol (2007) 1.53
Imaging in osteoarthritis. Rheum Dis Clin North Am (2008) 1.42
Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol (2007) 1.41
Factors affecting increasing radiation dose for mammography in North Carolina from 1997 through 2001: an analysis of Food and Drug Administration annual surveys. Acad Radiol (2004) 1.38
Why radiography should no longer be considered a surrogate outcome measure for longitudinal assessment of cartilage in knee osteoarthritis. Arthritis Res Ther (2011) 1.34
2007 Elizabeth Winston Lanier Award Winner. Magnetic resonance imaging of cartilage glycosaminoglycan: basic principles, imaging technique, and clinical applications. J Orthop Res (2008) 1.32
MRI of articular cartilage in OA: novel pulse sequences and compositional/functional markers. Osteoarthritis Cartilage (2006) 1.31
Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Clin Cancer Res (2010) 1.30
Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol (2008) 1.29
Radiographic and patient factors associated with pre-radiographic osteoarthritis in hip dysplasia. J Bone Joint Surg Am (2009) 1.28
Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol. Arthritis Rheum (2003) 1.27
Glycosaminoglycan distribution in cartilage as determined by delayed gadolinium-enhanced MRI of cartilage (dGEMRIC): potential clinical applications. AJR Am J Roentgenol (2004) 1.26
Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis (2012) 1.24
Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther (2011) 1.23
In vivo MRI of embryonic stem cells in a mouse model of myocardial infarction. Magn Reson Med (2004) 1.20
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer (2012) 1.17
Spatially-localized correlation of dGEMRIC-measured GAG distribution and mechanical stiffness in the human tibial plateau. J Orthop Res (2005) 1.14
Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry. J Clin Pharmacol (2010) 1.13
Three-dimensional delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) at 1.5T and 3.0T. J Magn Reson Imaging (2006) 1.09
Long-term outcome for patients with high volume retroperitoneal teratoma undergoing post-chemotherapy surgery. J Urol (2009) 1.07
Crystal structures of complexes containing domains from two viral internal ribosome entry site (IRES) RNAs bound to the 70S ribosome. Proc Natl Acad Sci U S A (2011) 1.06
Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in post-chemotherapy nonseminomatous testis cancer. J Urol (2002) 1.05
Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor? Cancer (2007) 1.04
Delayed gadolinium-enhanced magnetic resonance imaging of the meniscus: an index of meniscal tissue degeneration? Arthritis Rheum (2007) 1.04
The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review. Ann Rheum Dis (2011) 1.04
Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study. Arthritis Care Res (Hoboken) (2013) 1.03
Diffusion tensor imaging of native and degenerated human articular cartilage. Magn Reson Imaging (2006) 1.03
Perfusion MRI of U87 brain tumors in a mouse model. Magn Reson Med (2004) 1.03
Summary of worldwide pediatric malignancies reported after exposure to etanercept. Pediatr Rheumatol Online J (2010) 1.03
Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum (2005) 1.02
Delayed gadolinium-enhanced magnetic resonance imaging of cartilage in knee osteoarthritis: findings at different radiographic stages of disease and relationship to malalignment. Arthritis Rheum (2005) 1.02
Relaxivity and diffusion of gadolinium agents in cartilage. Magn Reson Med (2002) 1.01
Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS. J Pharm Biomed Anal (2011) 1.01
Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. J Clin Pharmacol (2013) 1.00
Suitability of T(1Gd) as the dGEMRIC index at 1.5T and 3.0T. Magn Reson Med (2007) 1.00
Hip dGEMRIC in asymptomatic volunteers and patients with early osteoarthritis: the influence of timing after contrast injection. Magn Reson Med (2007) 0.99
Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. Cancer Chemother Pharmacol (2010) 0.99
Comparison of delayed gadolinium enhanced MRI of cartilage (dGEMRIC) using inversion recovery and fast T1 mapping sequences. Magn Reson Med (2008) 0.99
Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses. J Immunol (2007) 0.99
Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol (2007) 0.98
Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum (2005) 0.96
Histology in mixed germ cell tumors. Is there a favorite pairing? J Urol (2004) 0.96
Osteoarthritis: current role of imaging. Med Clin North Am (2009) 0.96
Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection. J Clin Oncol (2005) 0.95
T2 of articular cartilage in the presence of Gd-DTPA2-. Magn Reson Med (2004) 0.95
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res (2009) 0.95
Investigation of the pharmacokinetics of romiplostim in rodents with a focus on the clearance mechanism. Pharm Res (2011) 0.95
A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology (Oxford) (2007) 0.94
Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? J Urol (2003) 0.93
Does retroperitoneal lymph node dissection have a curative role for patients with sex cord-stromal testicular tumors? Cancer (2003) 0.93
Three-dimensional T1 mapping for dGEMRIC at 3.0 T using the Look Locker method. Invest Radiol (2006) 0.93
Comparison of physician and patient global assessments over time in patients with rheumatoid arthritis: a retrospective analysis from the RADIUS cohort. J Clin Rheumatol (2013) 0.93
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors. Cancer Chemother Pharmacol (2010) 0.92
Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther (2012) 0.91
Differential recovery of glycosaminoglycan after IL-1-induced degradation of bovine articular cartilage depends on degree of degradation. Arthritis Res Ther (2003) 0.91
A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheumatol (2015) 0.90
Complications of post-chemotherapy retroperitoneal lymph node dissection for testis cancer. J Urol (2004) 0.90
Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res (2011) 0.90
RANKL inhibition: from mice to men (and women). Adv Exp Med Biol (2007) 0.90
Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. Cancer Chemother Pharmacol (2010) 0.89
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer (2011) 0.89
A modeling and simulation framework to support early clinical drug development decisions in oncology. J Clin Pharmacol (2010) 0.89
A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis. Arthritis Rheum (2007) 0.89
A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin Pharmacokinet (2002) 0.88
Serum lipids regulate dendritic cell CD1 expression and function. Immunology (2008) 0.88
Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemother Pharmacol (2012) 0.87
Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of Osteoarthritis of the knee. Arthritis Rheum (2005) 0.87
Relationship between cartilage stiffness and dGEMRIC index: correlation and prediction. J Orthop Res (2007) 0.87
Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis. Br J Clin Pharmacol (2006) 0.86